In this study, we demonstrated the antiepileptic effect of GS967 in the Scn1a+/− mouse model of Dravet syndrome, an unexpected result given that GS967 is a sodium channel blocker. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.